Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer

被引：0
|
作者：
Baker, Holly
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2021年 / 6卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [1] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    Takayuki Yoshino
    Maria Di Bartolomeo
    Kanwal Raghav
    Toshiki Masuishi
    Fotios Loupakis
    Hisato Kawakami
    Kensei Yamaguchi
    Tomohiro Nishina
    Zev Wainberg
    Elena Elez
    Javier Rodriguez
    Marwan Fakih
    Fortunato Ciardiello
    Kapil Saxena
    Kojiro Kobayashi
    Emarjola Bako
    Yasuyuki Okuda
    Gerold Meinhardt
    Axel Grothey
    Salvatore Siena
    Nature Communications, 14
  • [2] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [3] A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [4] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
    DiPeri, Timothy P.
    Evans, Kurt W.
    Raso, Maria Gabriela
    Zhao, Ming
    Rizvi, Yasmeen Q.
    Zheng, Xiaofeng
    Wang, Bailiang
    Kirby, Bryce P.
    Kong, Kathleen
    Kahle, Michael
    Yap, Timothy A.
    Dumbrava, Ecaterina E.
    Ajani, Jaffer A.
    Fu, Siqing
    Keyomarsi, Khandan
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4385 - 4398
  • [6] Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Yoshino, T.
    Iwata, H.
    Tamura, K.
    Takahashi, S.
    Redfern, C.
    Modi, S.
    Doi, T.
    Kawakami, H.
    Taniguchi, H.
    Takashima, A.
    Yamaguchi, K.
    Fisher, J.
    Li, B.
    Saito, K.
    Fujisaki, Y.
    Sugihara, M.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer
    Lazaratos, Anna-Maria
    Petrecca, Kevin
    Guiot, Marie-Christine
    Dankner, Matthew
    Jerzak, Katarzyna J.
    LANCET ONCOLOGY, 2024, 25 (07): : e282 - e282
  • [8] Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
    Rose, Peter G.
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 50
  • [9] HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
    Siena, Salvatore
    Raghav, Kanwal
    Masuishi, Toshiki
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Elez, Elena
    Rodriguez, Javier
    Chau, Ian
    Di Bartolomeo, Maria
    Kawakami, Hisato
    Suto, Fumitaka
    Koga, Makito
    Inaki, Koichiro
    Kuwahara, Yusuke
    Takehara, Issey
    Barrios, Daniel
    Kobayashi, Kojiro
    Grothey, Axel
    Yoshino, Takayuki
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [10] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
    Roodhart, Jeanine M. L.
    Koopman, Miriam
    LANCET ONCOLOGY, 2024, 25 (09): : 1104 - 1105
12345